#NewAseBioMember | “It is much more than an industry association; it is the meeting point for the entire biotechnology ecosystem in Spain”
Meet Fundación para la Investigación de Sanitas Hospitales, our new member. We spoke with José Francisco Tomás, president of FISH.
AseBio. What does your company's work bring to the table and what is its strength?
José Francisco Tomás. FISH offers something truly unique: the possibility of combining excellence in healthcare with biomedical research. Our strength lies in our cutting-edge hospitals and professionals who work closely with patients every day. This gives us the ability to transform scientific advances into real improvements in clinical practice. We are committed to strategic areas such as genomics, personalized medicine, artificial intelligence applied to biomedicine, and, of course, clinical trials, where we have taken a decisive step forward with the new Clinical Trials Unit at Blua Sanitas Valdebebas Hospital. This positions us uniquely to collaborate with the biotech and pharmaceutical industry and to accelerate patient access to the most innovative treatments.”
AseBio. What is AseBio for you?
José Francisco Tomás. It is much more than an industry association; it is the meeting point for the entire biotechnology ecosystem in Spain. It represents a space for genuine collaboration where connections are forged between science, business, academia, and healthcare. As a research foundation, we see AseBio as a platform that enables us to highlight our work, learn from other stakeholders, and join forces so that Spain continues to strengthen its position as a leading hub for clinical research and biotechnology.
AseBio. When did you first hear about AseBio?
José Francisco Tomás. We have long been familiar with AseBio’s track record and the impact it has had on the biotechnology sector in Spain. Its role in promoting biotechnology, advocating for the sector, and creating collaborative networks has positioned it as a benchmark in the innovation ecosystem
AseBio. What do you expect from being part of an association like AseBio?
José Francisco Tomás. We hope to participate actively, not just as observers. We want to share our lines of work—clinical trials, genomics, and AI applied to healthcare—while also learning from the experiences and projects of other partners. We believe that being part of AseBio will help us foster new collaborations, identify opportunities for joint research, and raise the visibility of private healthcare’s contribution to the development of biotechnology. In short, we want our membership to be valuable both for us and for the association as a whole.”
AseBio. What is the biggest challenge facing the biotech sector or your company?
José Francisco Tomás. The biggest challenge for the sector is to ensure that scientific innovation translates into real outcomes for patients. Biotechnology is advancing rapidly, but if we fail to bring these advances into hospitals and integrate them into clinical practice, we will fall short. For FISH, the challenge lies in fostering agile collaborative frameworks between private healthcare, universities, patient associations, and industry, so that research moves beyond the laboratory and drives real change in people’s lives. That is where we aim to play a leading role: supporting physician-researchers, generating meaningful knowledge, and accelerating the delivery of innovation to patients.